Therefore, for these types of cancer, only the combination therapy of SCD inhibitors and FADS2 inhibitors can block all compensatory pathways for tumor cells to acquire desaturated FAs, leading to impaired proliferation of tumor cells both in vitro and in vivo [71]. Here, FADS2 is linked to neoplasm.